What is it and what is it used forDabigatran Etexilate is a medicine known as an anticoagulant or blood thinner. It helps prevent and treat blood clots. It is used to reduce the risk of stroke and ...

Am J Health Syst Pharm. 2011;68(16):1506-1519. b These values are mean population values based on data from dabigatran doses ranging from 10 to 400 mg given as single and multiple doses.

All of them had atrial fibrillation. During the study span, 269,724 started using warfarin and 680,974 people began taking DOACs such as dabigatran, rivaroxaban, apixaban and edoxaban. The average ...

Another study compared Eliquis, Xarelto, Pradaxa (dabigatran), and Jantoven. The researchers found Eliquis to be the most favorable in terms of efficacy and safety. A study published in the Annals of ...

Department of Thrombosis and Hemostasis, Leiden University Medical Center, the Netherlands (S.J.V.d.W., F.A.K., M.V.H.). Department of Thrombosis and Hemostasis ...

Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from ...

BID indicates twice daily; INR, international normalized ratio; NA, not applicable; and RE-LY, Randomized Evaluation of Long Term Anticoagulant Therapy With Dabigatran Etexilate. * The differences ...

Methods We aimed to assess the consistency of efficacy and safety outcomes associated with dabigatran etexilate (DE) versus warfarin in patients with AF in LA from the RE-LY (Randomised Evaluation of ...

Outcome assessment was also blinded. There was one large phase III trial of the direct thrombin (factor IIa) inhibitor dabigatran. There were six phase II trials of factor Xa inhibitors, edoxaban, ...

However, there remains controversy about the overall net clinical benefit of PPIs (omeprazole, rabeprazole, pantoprazole, lansoprazole) when coprescribed with direct oral anticoagulants (DOACs; ...